Well-Defined Redox-Sensitive Polyethene Glycol-Paclitaxel Prodrug Conjugate for Tumor-Specific Delivery of Paclitaxel Using Octreotide for Tumor Targeting

Molecular Pharmaceutics

Volumn 12, Issue 8, 2015, Pages 3020-3031

  Yin, Tingjie ^a   Wu, Qu ^a   Wang, Lei ^a   Yin, Lifang ^a   Zhou, Jianping ^a   Huo, Meirong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

octreotide; paclitaxel; prodrug conjugate; redox sensitive; tumor therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; MACROGOL; OCTREOTIDE; PACLITAXEL; POLYMER; PRODRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER; MACROGOL DERIVATIVE; MICELLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SIZE; CELLULAR DISTRIBUTION; COMPARATIVE EFFECTIVENESS; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DISULFIDE BOND; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG SOLUBILITY; DRUG TARGETING; DRUG UPTAKE; ELECTRON SPIN RESONANCE; ENDOCYTOSIS; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER CELL LINE; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SLOW DRUG RELEASE; SMALL CELL LUNG CANCER; TISSUE DISTRIBUTION; TREATMENT DURATION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; HUMAN; LUNG NEOPLASMS; METABOLISM; MICELLE; NUDE MOUSE; PATHOLOGY; SMALL CELL LUNG CARCINOMA; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICELLES; OCTREOTIDE; OXIDATION-REDUCTION; PACLITAXEL; POLYETHYLENE GLYCOLS; POLYMERS; PRODRUGS; SMALL CELL LUNG CARCINOMA; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938528080     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00280     Document Type: Article

References (39)

1. Chen, M.-X.; Li, B.-K.; Yin, D.-K.; Liang, J.; Li, S.-S.; Peng, D.-Y. Layer-by-layer assembly of chitosan stabilized multilayered liposomes for paclitaxel delivery Carbohydr. Polym. 2014, 111, 298-304
2. de Weger, V. A.; Beijnen, J. H.; Schellens, J. H. Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel-a review Anti-Cancer drugs 2014, 25 (5) 488-494
3. Nehate, C.; Jain, S.; Saneja, A.; Khare, V.; Alam, N.; Dhar Dubey, R.; N Gupta, P. Paclitaxel formulations: challenges and novel delivery options Curr. Drug Delivery 2014, 11 (6) 666-686
4. Gao, X.; Wang, B.; Wu, Q.; Wei, X.; Zheng, F.; Men, K.; Shi, H.; Huang, N.; Wei, Y.; Gong, C. Combined delivery and anti-Cancer activity of paclitaxel and curcumin using polymeric micelles J. Biomed. Nanotechnol. 2015, 11 (4) 578-589
5. Meng, H.; Wang, M.; Liu, H.; Liu, X.; Situ, A.; Wu, B.; Ji, Z.; Chang, C. H.; Nel, A. E. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice ACS Nano 2015, 9, 3540-3557
6. Liu, J.; Zahedi, P.; Zeng, F.; Allen, C. Nano-sized assemblies of a PEG-docetaxel conjugate as a formulation strategy for docetaxel J. Pharm. Sci. 2008, 97 (8) 3274-3290
7. Mohanty, A. K.; Dilnawaz, F.; Mohanta, G. P.; Sahoo, S. K. Polymer-Drug Conjugates for Targeted Drug Delivery. In Targeted Drug Delivery: Concepts and Design; Springer: New York, 2015; pp 389-407.
8. Nam, K.; Nam, H. Y.; Kim, P.-H.; Kim, S. W. Paclitaxel-conjugated PEG and arginine-grafted bioreducible poly (disulfide amine) micelles for co-delivery of drug and gene Biomaterials 2012, 33 (32) 8122-8130
9. Li, C. Poly (L-glutamic acid)-anticancer drug conjugates Adv. Drug Delivery Rev. 2002, 54 (5) 695-713
10. Greco, F.; Vicent, M. J. Polymer-drug conjugates: current status and future trends Front. Biosci. 2008, 13, 2744-56
11. Zhang, H.; Huang, S.; Yang, X.; Zhai, G. Current research on hyaluronic acid-drug bioconjugates Eur. J. Med. Chem. 2014, 86, 310-317
12. Vllasaliu, D.; Fowler, R.; Stolnik, S. PEGylated nanomedicines: recent progress and remaining concerns Expert Opin. Drug delivery 2014, 11 (1) 139-154
13. Lu, J.; Chuan, X.; Zhang, H.; Dai, W.; Wang, X.; Wang, X.; Zhang, Q. Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: Preparation and comparison with other paclitaxel systems in vitro and in vivo Int. J. Pharm. 2014, 471 (1) 525-535
14. Pawar, S. K.; Badhwar, A. J.; Kharas, F.; Khandare, J. J.; Vavia, P. R. Design, synthesis and evaluation of N-acetyl glucosamine (NAG)-PEG-doxorubicin targeted conjugates for anticancer delivery Int. J. Pharm. 2012, 436 (1) 183-193
15. Fleming, A. B.; Haverstick, K.; Saltzman, W. M. In vitro cytotoxicity and in vivo distribution after direct delivery of PEG-camptothecin conjugates to the rat brain Bioconjugate Chem. 2004, 15 (6) 1364-1375
16. Kolate, A.; Baradia, D.; Patil, S.; Vhora, I.; Kore, G.; Misra, A. PEG-a versatile conjugating ligand for drugs and drug delivery systems J. Controlled Release 2014, 192, 67-81
17. Lv, S.; Tang, Z.; Zhang, D.; Song, W.; Li, M.; Lin, J.; Liu, H.; Chen, X. Well-defined polymer-drug conjugate engineered with redox and pH-sensitive release mechanism for efficient delivery of paclitaxel J. Controlled Release 2014, 194, 220-227
18. Froidevaux, S.; Eberle, A. N. Somatostatin analogs and radiopeptides in cancer therapy Pept. Sci. 2002, 66 (3) 161-183
19. Accardo, A.; Aloj, L.; Aurilio, M.; Morelli, G.; Tesauro, D. Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs Int. J. Nanomed. 2014, 9, 1537
20. Huo, M.; Zhu, Q.; Wu, Q.; Yin, T.; Wang, L.; Yin, L.; Zhou, J. Somatostatin Receptor-Mediated Specific Delivery of Paclitaxel Prodrugs for Efficient Cancer Therapy J. Pharm. Sci. 2015, 104, 2018-2028
21. Tabatabaei, S. N.; Girouard, H.; Carret, A.-S.; Martel, S. Remote control of the permeability of the blood-brain barrier by magnetic heating of nanoparticles: A proof of concept for brain drug delivery J. Controlled Release 2015, 206, 49-57
22. Saxena, V.; Gacchina Johnson, C.; Negussie, A. H.; Sharma, K. V.; Dreher, M. R.; Wood, B. J. Temperature-sensitive liposome-mediated delivery of thrombolytic agents Int. J. Hyperthermia 2015, 0, 1-7
23. Wang, T.-Y.; Choe, J. W.; Pu, K.; Devulapally, R.; Bachawal, S.; Machtaler, S.; Chowdhury, S. M.; Luong, R.; Tian, L.; Khuri-Yakub, B. Ultrasound-guided delivery of microRNA loaded nanoparticles into cancer J. Controlled Release 2015, 203, 99-108
24. Huu, V. A. N.; Luo, J.; Zhu, J.; Zhu, J.; Patel, S.; Boone, A.; Mahmoud, E.; McFearin, C.; Olejniczak, J.; de Gracia Lux, C. Light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye J. Controlled Release 2015, 200, 71-77
25. Bhatia, G.; Banga, A. K. Effect of Modulated Alternating and Direct Current Iontophoresis on Transdermal Delivery of Lidocaine Hydrochloride. BioMed Res. Int. 2014, 2014, Article ID 537941.
26. Yang, C.; Wang, X.; Yao, X.; Zhang, Y.; Wu, W.; Jiang, X. Hyaluronic acid nanogels with enzyme-sensitive cross-linking group for drug delivery J. Controlled Release 2015, 205, 206-217
27. Liu, J.; Huang, Y.; Kumar, A.; Tan, A.; Jin, S.; Mozhi, A.; Liang, X.-J. pH-Sensitive nano-systems for drug delivery in cancer therapy Biotechnol. Adv. 2014, 32 (4) 693-710
28. Li, J.; Yin, T.; Wang, L.; Yin, L.; Zhou, J.; Huo, M. Biological evaluation of redox-sensitive micelles based on hyaluronic acid-deoxycholic acid conjugates for tumor-specific delivery of paclitaxel Int. J. Pharm. 2015, 483 (1) 38-48
29. Brülisauer, L.; Gauthier, M. A.; Leroux, J.-C. Disulfide-containing parenteral delivery systems and their redox-biological fate J. Controlled Release 2014, 195, 147-154
30. Zhang, J.; Jin, W.; Wang, W.; Wang, J.; Zhang, X.; Zhang, Q. A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models Mol. Pharmaceutics 2010, 7 (4) 1159-1168
31. Li, C.; Yu, D.-F.; Newman, R. A.; Cabral, F.; Stephens, L. C.; Hunter, N.; Milas, L.; Wallace, S. Complete regression of well-established tumors using a novel water-soluble poly (L-glutamic acid)-paclitaxel conjugate Cancer Res. 1998, 58 (11) 2404-2409
32. Kakinoki, A.; Kaneo, Y.; Tanaka, T.; Hosokawa, Y. Synthesis and evaluation of water-soluble poly (vinyl alcohol)-paclitaxel conjugate as a macromolecular prodrug Biol. Pharm. Bull. 2008, 31 (5) 963-969
33. Santini, M. T.; Romano, R.; Rainaldi, G.; Filippini, P.; Bravo, E.; Porcu, L.; Motta, A.; Calcabrini, A.; Meschini, S.; Indovina, P. L. The relationship between 1 H-NMR mobile lipid intensity and cholesterol in two human tumor multidrug resistant cell lines (MCF-7 and LoVo) Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 2001, 1531 (1) 111-131
34. Cavallaro, G.; Maniscalco, L.; Campisi, M.; Schillaci, D.; Giammona, G. Synthesis, characterization and in vitro cytotoxicity studies of a macromolecular conjugate of paclitaxel bearing oxytocin as targeting moiety Eur. J. Pharm. Biopharm. 2007, 66 (2) 182-192
35. Khandare, J. J.; Jayant, S.; Singh, A.; Chandna, P.; Wang, Y.; Vorsa, N.; Minko, T. Dendrimer versus linear conjugate: influence of polymeric architecture on the delivery and anticancer effect of paclitaxel Bioconjugate Chem. 2006, 17 (6) 1464-1472
36. Greenwald, R. B.; Choe, Y. H.; McGuire, J.; Conover, C. D. Effective drug delivery by PEGylated drug conjugates Adv. Drug Delivery Rev. 2003, 55 (2) 217-250
37. Albini, A.; Sporn, M. B. The tumour microenvironment as a target for chemoprevention Nat. Rev. Cancer 2007, 7 (2) 139-147
38. Cook, J. A.; Pass, H. I.; Iype, S. N.; Friedman, N.; DeGraff, W.; Russo, A.; Mitchell, J. B. Cellular glutathione and thiol measurements from surgically resected human lung tumor and normal lung tissue Cancer Res. 1991, 51 (16) 4287-4294
39. Fang, J.; Nakamura, H.; Maeda, H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Adv. Drug Delivery Rev. 2011, 63 (3) 136-151